Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
ASCO GU 2025: Darolutamide Triplet Therapy Outperforms Alternatives in Advanced Prostate Cancer
/in Retrospective studies/by MaxAI Strikes Again: FDA Cleared an AI That Outperformed Human Pathologists in Missed Cases
/in Artificial Intelligence/by MaxUpdate Phase 1: Mevrometostat Shows Promise in Prostate Cancer by Targeting EZH2
/in Clinical Trial, Metastatic, Phase 1/by MaxThe Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment
/in Clinical Trial, Not PCa related/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxHyperthermia: Where Are We With Solid Tumors?
/in Hyperthermia, Preclinical Research/by MaxNew Anti-Metastatic Agent Adhibin Discovered: A Potential Game Changer in Cancer Treatment
/in Preclinical Research/by MaxPioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by Max